Last Updated: 14 Oct 2024
Executive Summary
Paranovus Entertainment Technology Ltd. (PAVS) is a Chinese nutraceutical and dietary supplement manufacturer with a market capitalization of $46.88 million. Despite a strong operating margin of 31.53%, the company has been struggling with profitability, recording a negative EBITDA of $2.43 million and a profit margin of -1.55% for the trailing twelve months. The stock price has declined significantly in the past year, currently trading at $0.70.
Company Overview
Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in China and internationally. The company's products include a range of vitamins, minerals, and herbal supplements, as well as functional foods and beverages.
Fundamental Analysis
Revenue: PAVS reported revenue of $6.54 million for the trailing twelve months, a 0.96% decrease year-over-year.
Earnings: The company reported diluted earnings per share (EPS) of $0.75 for the trailing twelve months.
Profitability: PAVS has been struggling with profitability, with a negative EBITDA of $2.43 million and a profit margin of -1.55% for the trailing twelve months.
Balance Sheet: As of June 30, 2024, PAVS had total assets of $28.27 million and total liabilities of $22.65 million, resulting in a book value of $0.76 per share.
Technical Analysis
Price Action: PAVS has been trending lower in recent months, breaking below its 50-day and 200-day moving averages.
Support and Resistance: The stock has support at $0.65 and resistance at $0.80.
Momentum Indicators: The relative strength index (RSI) is below 30, indicating that the stock is oversold.
Short Term Outlook
In the short term, PAVS is likely to remain under pressure due to its weak profitability and declining revenue. The stock could test support at $0.65 in the coming weeks.
Long Term Outlook
The long-term outlook for PAVS is uncertain. The company needs to improve its profitability and revenue growth in order to attract investors. If PAVS can execute on its growth plans, it could be a potential turnaround story.
Analyst Recommendations
Currently, there are no analyst recommendations available for PAVS.
